MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/coc.0000000000001265

Медицинская библиотека · American journal of clinical oncology · 2025

Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting: A Systematic Review and Meta-Analysis.

Krishnan Nupur, Lee Patsy, Boldt Gabriel, Lakkunarajah Suganija, Verma Saurav, Blanchette Phillip, Raphael Jacques

СтатьяСистематический обзорМетаанализПеревод пока не подготовлен

Аннотация

OBJECTIVES

Despite a good response to first-line chemotherapy, small-cell lung cancer (SCLC) has high relapse rates and a poor prognosis. We conducted a systematic review and meta-analysis to assess the role of immune checkpoint inhibitors (ICIs) in the treatment of extended stage SCLC (ES-SCLC), in different lines of therapy.

METHODS

Medline (PubMed), EMBASE, and Cochrane Library databases between January 2010 and March 2025 and conference proceedings between 2018 and 2025 were searched for RCTs assessing ICIs versus chemotherapy in patients with ES-SCLC. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and grade 3+ adverse events. Pooled hazard ratios (HR) for OS and PFS were meta-analyzed using the generic inverse variance method, and random-effect models were used to compute pooled estimates. Subgroup analyses compared survival by line of therapy, sex, age, and ECOG status.

RESULTS

ICIs decreased risk of death by 19% (HR: 0.81, 95% CI: 0.76-0.86). OS benefit was regardless of age, sex, or ECOG, but only in first-line treatment. ICIs decreased the risk of disease progression by 22% (HR: 0.78, 95% CI: 0.67-0.91), with PFS benefit restricted to first-line treatment with a detrimental effect in the second line. ICIs improved ORR (OR: 0.79, 95% CI: 0.66-0.95), but were associated with increased grade 3+diarrhea (OR: 3.63, 95% CI: 1.46-9.02).

CONCLUSIONS

ICIs conferred efficacy benefits and an acceptable safety profile in the treatment of patients with ES-SCLC in the first-line, but should not be used in the second-line as single agents. Biomarkers predicting long-term benefit are needed to further improve outcomes.

Для цитирования: Krishnan Nupur, Lee Patsy, Boldt Gabriel, Lakkunarajah Suganija, Verma Saurav, Blanchette Phillip, Raphael Jacques. Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting: A Systematic Review and Meta-Analysis.. American journal of clinical oncology. 2025. DOI: 10.1097/coc.0000000000001265.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.